INDOLENT NON-HODGKIN LYMPHOMA
Clinical trials for INDOLENT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new INDOLENT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for INDOLENT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell therapy for tough blood cancers put on hold
Disease control TerminatedThis early-stage study tested a new treatment called CNTY-101 for people with B-cell cancers that came back or didn't respond to other therapies. The main goals were to find a safe dose and see if the treatment could shrink tumors. The study was stopped early, so results are limi…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Century Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Drug combo aims to control Slow-Growing lymphoma without chemo
Disease control TerminatedThis phase 2 study tested a combination of two drugs, lenalidomide and rituximab, in 30 people with previously untreated indolent non-Hodgkin's lymphoma. The goal was to see how well the drugs worked together to shrink or control the cancer. Participants took lenalidomide daily f…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC